NCT03326102: PK, Efficacy and Safety Study of DHP107 in Patients With Recurrent or Metastatic Breast Cancer

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Symptomatic, untreated metastases to the central nervous system (CNS)

Comments are closed.

Up ↑